Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 4, 2025
Daily News
November 4, 2025
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Daiichi Sankyo’s Profit Down on HER3-DXd Delay, One-Off CMO Costs
November 4, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Toho Adopts Poison Pill in Response to 3D’s Rising Stake
November 4, 2025
- Meiji-Daito Consortium Discussing Integration of 56 Generic Products
November 4, 2025
- J&J Seeks Nod for Talvey-Tecvayli Bispecific Combo in Multiple Myeloma
November 4, 2025
- Alpha Fusion Launches PI of Lead Radiopharmaceutical in Thyroid Cancer
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
- Ayumi to Take Over Astellas, Ono Osteoporosis Drugs
November 4, 2025
- Fuji Inks Deal with Daiichi on Ranmark Biosimilar, Now Plans 2026 Launch
November 4, 2025
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
- Otsuka Snags APAC Rights to 4DMT’s AMD Gene Therapy
November 4, 2025
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…